|
Delayed
Sao Paulo
04:06:59 06/11/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 78.14 BRL | -2.14% |
|
+5.61% | +36.30% |
| 04:48am | Maxim Adjusts Price Target on Gilead Sciences to $200 From $165 | MT |
| 04:28am | Gilead Sciences' Phase 3 Livdelzi Study Shows Improvements in Adults With Primary Biliary Cholangitis | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -2.80% | +0.82% | +21.15% | +18.38% | +28.87% | +49.59% | +132.68% | +422.60% | +1,774.53% | 1,263B | |
| -1.18% | -0.45% | +8.32% | +6.36% | +32.38% | +47.30% | +80.60% | +67.64% | +134.84% | 665B | |
| -1.54% | +0.30% | +9.74% | +18.46% | +27.64% | +34.54% | +106.55% | +148.89% | +395.08% | 521B | |
| -1.06% | -2.49% | +12.27% | +7.40% | +19.35% | +47.76% | +65.17% | +7.52% | +74.40% | 387B | |
| -1.83% | +1.40% | +6.34% | +15.62% | +40.97% | +75.83% | +42.21% | +81.82% | +147.09% | 371B | |
| -0.10% | +1.38% | +15.14% | +7.76% | +22.37% | +32.03% | +59.21% | +76.26% | +93.54% | 310B | |
| +0.13% | +7.59% | +19.36% | +16.67% | +1.83% | +12.79% | +36.65% | +50.84% | +216.94% | 293B | |
| -2.88% | +1.44% | +15.98% | +14.60% | +42.79% | +46.12% | +71.30% | +118.63% | +235.73% | 259B | |
| -3.56% | +2.28% | +17.11% | +28.55% | +38.00% | +38.18% | +108.75% | +155.40% | +128.89% | 216B | |
| -4.89% | +4.19% | +9.91% | -7.83% | -16.60% | -9.90% | -61.31% | -25.22% | +135.77% | 189B | |
| -2.09% | +1.02% | +10.38% | +17.22% | +21.51% | +22.94% | -2.97% | -37.76% | -0.41% | 175B | |
| -0.87% | +1.27% | +8.61% | +12.79% | +20.62% | +31.14% | +41.76% | +183.56% | +557.11% | 139B | |
| -1.60% | +3.15% | +7.68% | -0.48% | +17.40% | +36.27% | +19.96% | +6.52% | +20.34% | 131B | |
| +0.88% | +10.46% | +18.35% | +23.51% | +32.08% | +28.33% | +135.53% | +388.72% | +705.48% | 125B | |
| +0.51% | +11.00% | +20.77% | +13.46% | +2.19% | -0.82% | -0.48% | -4.44% | +16.96% | 113B | |
| 0.00% | +4.19% | +7.45% | -1.33% | +3.59% | +5.70% | +34.52% | -4.06% | -2.39% | 102B | |
| -2.46% | +11.02% | +25.13% | +18.27% | +17.77% | +41.11% | +9.20% | +48.64% | +148.78% | 93.39B | |
| -6.68% | +9.19% | +19.69% | +332.36% | +724.77% | +932.36% | +237.48% | +2.63% | - | 103B | |
| -0.07% | +0.03% | +10.51% | +3.69% | +22.63% | +36.06% | +2.56% | -25.68% | +62.89% | 73.41B | |
| Average | -1.68% | +7.18% | +13.89% | +28.71% | +57.90% | +79.33% | +58.91% | +87.50% | +269.20% | 291.05B | |
| Weighted average by Cap. | -1.80% | +6.49% | +14.30% | +19.32% | +38.04% | +56.15% | +77.93% | +155.16% | +555.71% |
- Stock Market
- Stocks
- GILD Stock
- GILD34 Stock
- Sector Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
